| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
155,668 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$5,222,943 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
162,341 |
|
|
| Total
Value |
$5,222,943 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2023-06-02 |
40,493 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
180 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-12-05 |
4 |
D |
$12.84 |
$22,945 |
D/D |
(1,787) |
6,439 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-12-12 |
4 |
AS |
$12.92 |
$38,760 |
D/D |
(3,000) |
3,439 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-01-03 |
4 |
D |
$13.81 |
$60,557 |
D/D |
(4,385) |
11,786 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-01-17 |
4 |
AS |
$13.93 |
$97,510 |
D/D |
(7,000) |
4,386 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
Senior Vice President and CFO |
• – – |
2004-01-13 |
4 |
A |
$14.67 |
$10,000 |
I/I |
682 |
1,524 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-02-25 |
4 |
OE |
$15.58 |
$194,734 |
D/D |
12,499 |
29,075 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-02-25 |
4 |
D |
$15.58 |
$67,259 |
D/D |
(4,317) |
25,510 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2022-06-06 |
4 |
AS |
$19.25 |
$123,673 |
D/D |
(6,424) |
33,980 |
0 |
% |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-01-24 |
4 |
A |
$19.31 |
$6,488 |
I/I |
336 |
1,860 |
|
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-06-07 |
4 |
S |
$19.31 |
$19,562 |
D/D |
(1,013) |
1,237 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-04-02 |
4 |
S |
$19.91 |
$2,807,887 |
D/D |
(141,029) |
73,439 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-04-09 |
4 |
D |
$19.94 |
$118,643 |
D/D |
(5,950) |
67,489 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2023-06-02 |
4 |
AS |
$23.01 |
$198,760 |
D/D |
(8,638) |
40,493 |
0 |
% |
|
| CVTX |
CV Therapeutics Inc |
Senior Vice President and CFO |
• – – |
2004-12-16 |
4 |
S |
$23.86 |
$178,954 |
D/D |
(7,500) |
19,988 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-01-03 |
4 |
D |
$24.76 |
$1,263 |
D/D |
(51) |
886 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-11-03 |
4 |
S |
$25.21 |
$668,065 |
D/D |
(26,500) |
0 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-08-26 |
4 |
S |
$26.24 |
$564,317 |
D/D |
(21,506) |
0 |
|
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2021-05-28 |
4 |
AS |
$28.99 |
$207,023 |
D/D |
(7,142) |
13,420 |
0 |
% |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2021-06-17 |
4 |
AS |
$30.52 |
$95,795 |
D/D |
(3,139) |
23,129 |
0 |
% |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-09-01 |
4 |
D |
$32.00 |
$72,000 |
D/D |
(2,250) |
0 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-09-01 |
4 |
D |
$32.00 |
$39,584 |
D/D |
(1,237) |
2,250 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-05-01 |
4 |
OE |
$39.06 |
$1,093,680 |
D/D |
28,000 |
61,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-09-04 |
4 |
OE |
$39.06 |
$351,540 |
D/D |
9,000 |
46,950 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-12-02 |
4 |
OE |
$39.06 |
$351,540 |
D/D |
9,000 |
46,950 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-03-03 |
4 |
OE |
$39.06 |
$312,480 |
D/D |
8,000 |
72,273 |
0 |
- |
|
180 Records found
|
|
Page 4 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
